Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol

Clinical Pharmacokinetics

Volumn 37, Issue SUPPL. 2, 1999, Pages 41-51

  Bramer, Steven L ^a   Suri, Ajit ^a  

^a OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CILOSTAZOL; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 ISOENZYME; DRUG METABOLITE; DRUG METABOLIZING ENZYME; METOPROLOL; QUINIDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG URINE LEVEL; ENZYME DEFICIENCY; ENZYME INHIBITION; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; PAIN; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; VOLUNTEER;

EID: 0033495930     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199937002-00005     Document Type: Article

References (25)

1. Bramer SL, Tata PNV, Mallikaarjun S, et al. Disposition of 14C-cilostazol after single dose administration to healthy human subjects [abstract No. 3452]. American Association of Pharmaceutical Scientists Annual Meeting; 1997 Nov 2-6; Boston. Pharm Res 1997; 14 Suppl. 11: S612
2. Abbas R, Chow CP, Browder NJ, el al. In vitro metabolism and interaction of cilostazol with human hepatic cytochrome P450 isoforms. Hum Exp Toxicol. In press
3. Suri A, Forbes WP, Bramer SL. The effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet 1999; 37 Suppl. 2: 61-8
4. Bramer SL, Suri A. Effect of omeprazole on the metabolism of cilostazol. Clin Pharmacokinet 1999; 37 Suppl. 2: 53-9
5. Zhou H-H, Anthony LB, Roden DM, et al. Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation. Clin Pharmacol Ther 1990; 47: 686-93
6. Koyama E, Sohn DR, Shin SG, et al. Metabolic disposition of imipramine in oriental subjects: relation to metoprolol α-hydroxylation and S-mephenytoin 4′-hydroxylation phenotypes. J Pharmacol Exp Ther 1994; 271: 860-7
7. McGourty JC, Silas JH, Lennard MS, et al. Metoprolol metabolism and debrisoquine oxidation polymorphism - population and family studies. Br J Clin Pharmacol 1985; 20: 555-66
8. Schmid B, Bircher J, Preisig R, et al. Polymorphic dextromethorphan metabolism: co-segregation of oxidative 0-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 1985; 38 (6): 618-24
9. Fu CJ, Tata PNV, Bramer SL. Simultaneous quantitative determination of cilostazol and its metabolites in plasma by high performance liquid chromatography. J Chromatogr B Biomed Sci App 1999; 728 (2): 251-62
10. Tata PNV, Fu CJ, Bramer SL. Determination of cilostazol and its metabolites in human urine by high performance liquid chromatography. J Pharm Biomed Anal. In press
11. Guentert TW, Rakhit A, Upton RA, et al. An integrated approach to measurements of quinidine and metabolites in biological fluids. J Chromatogr 1980 Oct 10; 183 (4): 514-8
12. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982: 332-6
13. Ochs HR, Greenblatt DJ, Woo E. Clinical pharmacokinetics of quinidine. Clin Pharmacokinet 1980 Mar-Apr; 5 (2): 150-68
14. Otton SV, Schadel M, Cheung SW, et al. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin Pharmacol Ther 1993; 54: 463-72
15. Schellens JHM, Ghabrial H, Van der Wart HHF, et al. Differential effects of quinidine on the disposition of nifedipine, sparteine, and mephenytoin in humans. Clin Pharmacol Ther 1991; 50: 520-8
16. Greenblatt DJ, Pfeifer HJ, Ochs HR, et al. Pharmacokinetics of quinidine in humans after Intravenous, intramuscular and oral administration. J Pharmacol Exp Ther 1977; 202: 365-78
17. Sandberg A, Abrahamsson B, Svenheden A, et al. Steady-state bioavailability and day-to-day variability of a multiple-unit (CR/ZOK) and a single-unit (OROS) delivery system of metoprolol after once-daily dosing. Pharm Res 1993 Jan; 10 (1): 28-34
18. Shimizu H, Noguchi H, Uno K. Variation of pharmacokinetics after oral administration of slow-release metoprolol tablets and pharmacogenetic considerations. Arzneimittelforschung 1992; 42: 802-6
19. Sohn DR, Kusaka M, Shin SG, et al. Utility of a one-point (3 hour postdose) plasma metabolic ratio as a phenotyping test using metoprolol in two east Asian populations. Drug Monit 1992; 14: 184-9
20. Lennard MS, Silas JH, Freestone S, et al. Oxidative phenotype - a major determinant of metoprolol metabolism and response. N Engl J Med 1982; 307: 1558-60
21. Horai Y, Nakano M, Ishizaki T, et al. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 1989; 46: 198-207
22. Horai Y, Taga J, Ishizaki T, et al. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population. Br J Clin Pharmacol 1990; 29: 111-5
23. Sohn DR, Shin SG, Park CW, et al. Metoprolol oxidation polymorphism in a Korean population: comparison with native Japanese and Chinese populations. Br J Clin Pharmacol 1991; 32: 504-7
24. Bramer SL, Forbes WP, Mallikaarjun S. Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease. Clin Pharmacokinet 1999; 37 Suppl. 2: 1-11
25. Long JW. The essential guide to prescription drugs. New York: Harper Collins, 1995: 892-6